Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2598)
All Articles published online
|
May 21, 2011 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Abbadessa G, Rimassa L, Pressiani T, Carrillo-Infante C, Cucchi E, Santoro A. Optimized management of advanced hepatocellular carcinoma: Four long-lasting responses to sorafenib. World J Gastroenterol 2011; 17(19): 2450-2453 [PMID: 21633647 DOI: 10.3748/wjg.v17.i19.2450] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v17/i19/2450.htm |
| Number | Citing Articles |
| 1 |
Luigi Bolondi, Antonio Craxi, Franco Trevisani, Bruno Daniele, Giovan Giuseppe Di Costanzo, Stefano Fagiuoli, Calogero Cammà, Paolo Bruzzi, Romano Danesi, Federico Spandonaro, Corrado Boni, Armando Santoro, Massimo Colombo. Refining sorafenib therapy: lessons from clinical practice. Future Oncology 2015; 11(3): 449 doi: 10.2217/fon.14.261
|
| 2 |
Florian Poullenot, Paulette Bioulac-Sage, Hervé Laumonier, Jean Saric, Thibault Carteret, Jean-Frédéric Blanc. Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: Could we stop the treatment? About four cases. Acta Oncologica 2014; 53(3): 420 doi: 10.3109/0284186X.2013.795286
|
| 3 |
Takeshi Koujima, Yoshikatsu Endo, Takeharu Yamamoto, Toshifumi Tada, Kazuhiko Morii, Shinichiro Nakamura, Kyohei Kai. Long-term sustained complete response with off-therapy to sorafenib in advanced hepatocellular carcinoma: a case report. Kanzo 2020; 61(5): 255 doi: 10.2957/kanzo.61.255
|
| 4 |
Rodolfo Sacco, Lorenzo Faggioni, Irene Bargellini, Antonio Romano, Marco Bertini, Barbara Ginanni, Valentina Battaglia, Michele Bertoni, Elena Bozzi, Graziana Federici, Salvatore Metrangolo, Giuseppe Parisi, Emanuele Neri, Elisabetta Sodini, Emanuele Tumino, Giampaolo Bresci, Carlo Bartolozzi. Treatment Response After Unusual Low Dose Sorafenib: Diagnosis with Perfusion CT and Follow-up in a Patient with Recurrent Hepatocellular Carcinoma. Journal of Gastrointestinal Cancer 2012; 43(S1): 234 doi: 10.1007/s12029-012-9403-4
|
| 5 |
Linda Calistri, Cesare Cordopatri, Cosimo Nardi, Elena Gianni, Fabio Marra, Stefano Colagrande. Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis. Molecular and Clinical Oncology 2017; 6(3): 389 doi: 10.3892/mco.2017.1132
|
| 6 |
Norihito Nakano, Tomokazu Kawaoka, Hiroshi Aikata, Fumi Honda, Yuki Nakamura, Kei Morio, Masahiro Hatooka, Takayuki Fukuhara, Tomoki Kobayashi, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Shoichi Takahashi, Kazuaki Chayama. Complete response to short‐term sorafenib treatment alone for hepatocellular carcinoma with bone, lymph node, and peritoneum metastases. Hepatology Research 2016; 46(13): 1402 doi: 10.1111/hepr.12698
|
| 7 |
ASSUNTA MARIA TERESA GERARDI, LUCA PIO STOPPINO, ARCANGELO LISO, LUCA MACARINI, MATTEO LANDRISCINA. Rapid long-lasting biochemical and radiological response to sorafenib in a case of advanced hepatocellular carcinoma. Oncology Letters 2013; 5(3): 975 doi: 10.3892/ol.2013.1131
|
| 8 |
Francesco Tovoli, Luca Ielasi, Andrea Casadei-Gardini, Alessandro Granito, Francesco Giuseppe Foschi, Giulia Rovesti, Giulia Negrini, Giulia Orsi, Matteo Renzulli, Fabio Piscaglia. Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. Journal of Hepatology 2019; 71(6): 1175 doi: 10.1016/j.jhep.2019.08.015
|
| 9 |
Faouzi Djebbari, Nicola Stoner, Verna Teresa Lavender. A systematic review of non-standard dosing of oral anticancer therapies. BMC Cancer 2018; 18(1) doi: 10.1186/s12885-018-5066-2
|
| 10 |
Nisha Sahu, Samrat Rakshit, L.V.K.S. Bhaskar. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma. 2022; : 33 doi: 10.1016/B978-0-323-98806-3.00023-4
|
| 11 |
HARUHIKO TAKEDA, HIROKI NISHIKAWA, ERIKO IGUCHI, YOSHIAKI OHARA, AZUSA SAKAMOTO, KEIICHI HATAMARU, SHINICHIRO HENMI, SUMIO SAITO, AKIHIRO NASU, HIDEYUKI KOMEKADO, RYUICHI KITA, TORU KIMURA, YUKIO OSAKI. Impact of pretreatment serum cholinesterase level in unresectable advanced hepatocellular carcinoma patients treated with sorafenib. Molecular and Clinical Oncology 2013; 1(2): 241 doi: 10.3892/mco.2012.48
|
| 12 |
Marco Moroni, Laura Zanlorenzi. Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma. Future Oncology 2013; 9(8): 1231 doi: 10.2217/fon.13.86
|
| 13 |
Matthias Pinter, Wolfgang Sieghart. Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure?. memo - Magazine of European Medical Oncology 2018; 11(3): 185 doi: 10.1007/s12254-018-0431-z
|
| 14 |
JUAN DU, XIAOPING QIAN, BAORUI LIU. Long-term progression-free survival in a case of hepatocellular carcinoma with vertebral metastasis treated with a reduced dose of sorafenib: Case report and review of the literature. Oncology Letters 2013; 5(1): 381 doi: 10.3892/ol.2012.974
|
| 15 |
Masahiro Shinoda, Norihiro Kishida, Osamu Itano, Shigenori Ei, Akihisa Ueno, Minoru Kitago, Yuta Abe, Taizo Hibi, Hiroshi Yagi, Yohei Masugi, Minoru Tanabe, Koichi Aiura, Michiie Sakamaoto, Akihiro Tanimoto, Yuko Kitagawa. Long-term complete response of advanced hepatocellular carcinoma treated with multidisciplinary therapy including reduced dose of sorafenib: case report and review of the literature. World Journal of Surgical Oncology 2015; 13(1) doi: 10.1186/s12957-015-0559-9
|
| 16 |
Rodolfo Sacco, Irene Bargellini, Barbara Ginanni, Marco Bertini, Lorenzo Faggioni, Graziana Federici, Antonio Romano, Michele Bertoni, Salvatore Metrangolo, Emanuele Altomare, Giuseppe Parisi, Emanuele Tumino, Antonio Scaramuzzino, Giampaolo Bresci, Carlo Bartolozzi. Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?. Expert Review of Anticancer Therapy 2012; 12(7): 869 doi: 10.1586/era.12.58
|
| 17 |
Haruhiko Takeda, Hiroki Nishikawa, Eriko Iguchi, Yoshiaki Ohara, Azusa Sakamoto, Sumio Saito, Norihiro Nishijima, Akihiro Nasu, Hideyuki Komekado, Ryuichi Kita, Toru Kimura, Yukio Osaki. Effect of treatment with branched‐chain amino acids during sorafenib therapy for unresectable hepatocellular carcinoma. Hepatology Research 2014; 44(3): 302 doi: 10.1111/hepr.12125
|
| 18 |
Peipei Song, Ruoyan G. Tobe, Yoshinori Inagaki, Norihiro Kokudo, Kiyoshi Hasegawa, Yasuhiko Sugawara, Wei Tang. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver International 2012; 32(7): 1053 doi: 10.1111/j.1478-3231.2012.02792.x
|
| 19 |
Satoshi Shiba, Takuji Okusaka, Masafumi Ikeda, Hidetsugu Saito, Takafumi Ichida. Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib. Hepatology Research 2014; 44(13): 1268 doi: 10.1111/hepr.12297
|
| 20 |
Jan Peveling-Oberhag, Claudia Döring, Sylvia Hartmann, Natalie Filmann, Angelika Mertens, Albrecht Piiper, Eva Herrmann, Martin-Leo Hansmann, Stefan Zeuzem, Jörg Trojan, Martin-Walter Welker. Feasibility of global miRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib. Clinical Science 2015; 128(1): 29 doi: 10.1042/CS20140007
|
| 21 |
Haruhiko Takeda, Hiroki Nishikawa, Yukio Osaki, Kaoru Tsuchiya, Kouji Joko, Chikara Ogawa, Hiroyoshi Taniguchi, Etsuro Orito, Yasushi Uchida, Namiki Izumi. Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma. Hepatology Research 2015; 45(10) doi: 10.1111/hepr.12480
|
| 22 |
Michitoshi Takano, Takashi Kokudo, Yoshihiro Miyazaki, Yumiko Kageyama, Amane Takahashi, Katsumi Amikura, Hirohiko Sakamoto. Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma. World Journal of Gastroenterology 2016; 22(42): 9445-9450 doi: 10.3748/wjg.v22.i42.9445
|